Scinai Immunotherapeutics (SCNI)
NASDAQ:SCNI
Top Page
Scinai Immunotherapeutics
(NASDAQ:SCNI)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.98
▲(25.00% Upside)
Action:UpgradedDate:01/27/26
The score is held back primarily by weak financial performance—persistent operating losses and continued cash burn despite recent balance sheet improvement. Technicals are a moderate positive with the stock trading above key short-term averages and mildly positive momentum, while valuation is constrained by a negative P/E and no dividend support.
Positive Factors
Balance sheet improvement
The shift to positive equity and lower leverage in 2024 materially strengthens financial flexibility versus prior years. This improved capital structure provides a longer runway for R&D and operations, reducing near-term refinancing pressure and lowering the probability of forced dilutive raises.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow indicate the company continues to consume cash to fund R&D and operations. Over multiple years this creates reliance on external financing, increasing dilution risk and constraining the ability to invest opportunistically without consistent positive cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet improvement
The shift to positive equity and lower leverage in 2024 materially strengthens financial flexibility versus prior years. This improved capital structure provides a longer runway for R&D and operations, reducing near-term refinancing pressure and lowering the probability of forced dilutive raises.
Read all positive factors
Scinai Immunotherapeutics (SCNI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$512.65K
Dividend YieldN/A
Average Volume (3M)101.31K
Price to Earnings (P/E)―
Beta (1Y)1.42
Revenue Growth178.82%
EPS Growth-4121.10%
CountryUS
Employees31
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.74
Shares Outstanding3,187,679
10 Day Avg. Volume127,573
30 Day Avg. Volume101,310
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.27
Price to Sales (P/S)4.11
P/FCF Ratio-0.43
Enterprise Value/Market Cap4.21
Enterprise Value/Revenue1.88
Enterprise Value/Gross Profit-1.28
Enterprise Value/Ebitda0.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Scinai Immunotherapeutics Business Overview & Revenue Model
Company Description
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel...
How the Company Makes Money
Scinai Immunotherapeutics generates revenue primarily through the development and commercialization of its immunotherapeutic products. The company earns money by progressing its drug candidates through clinical trials, obtaining regulatory approva...
Scinai Immunotherapeutics Earnings Call Summary
Earnings Call Date:Aug 15, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive and negative aspects. While there were notable achievements such as the reduction in net loss, positive regulatory feedback, and growth in the CDMO business, there were also challenges like a significant decrease in cash position and negative shareholder equity. The sentiment is balanced with both opportunities and financial restructuring challenges.Positive Updates
Reduction in Operating Expenses
R&D expenses decreased to $2.79 million compared to $3.45 million the previous year, and marketing and G&A expenses were reduced to $1 million from $2.3 million the previous year.
Negative Updates
Cash Position Decrease
Cash available as of June 30, 2024, was $3.21 million, down from $7.63 million at the end of June 30, 2023.
Read all updates
Q2-2024 Updates
Positive
Negative
Reduction in Operating Expenses
R&D expenses decreased to $2.79 million compared to $3.45 million the previous year, and marketing and G&A expenses were reduced to $1 million from $2.3 million the previous year.
Read all positive updates
Company Guidance
In the Q2 2024 earnings call for Scinai Immunotherapeutics, CEO Amir Reichman provided detailed guidance on the company's strategic objectives and financial outlook. Scinai aims to fast-track IL-17 development to toxicology studies and increase CDMO business unit sales to $1.25 million. The company plans to reduce R&D risks by partnering with other pharma companies while maintaining careful spending to control its burn rate. Financially, Scinai reported a net loss of $4.48 million for the first half of 2024, a decrease from $7.28 million in the same period in 2023, attributed to reduced operating expenses. In addition, Scinai is working on a debt-to-equity restructuring deal expected to positively impact shareholder equity by approximately $19 million. The company also announced a $2 million equity commitment from Daniel Stone, which will provide additional financial flexibility. Overall, the guidance highlights Scinai's focus on advancing its R&D pipeline and CDMO business while ensuring financial stability and growth.Scinai Immunotherapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.15M | 658.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.69M | -580.00K | -512.67K | -559.80K | -747.65K | -708.92K |
| EBITDA | 8.80M | -6.99M | -9.19M | -10.50M | -10.39M | 2.75M |
| Net Income | 4.61M | 4.80M | -6.50M | -5.80M | -8.21M | -1.39M |
Balance Sheet | ||||||
| Total Assets | 11.84M | 13.45M | 17.47M | 27.07M | 32.04M | 17.71M |
| Cash, Cash Equivalents and Short-Term Investments | 989.00K | 1.96M | 4.87M | 14.07M | 17.37M | 2.93M |
| Total Debt | 2.36M | 2.09M | 20.56M | 21.54M | 29.23M | 20.90M |
| Total Liabilities | 3.98M | 3.47M | 22.04M | 28.83M | 31.05M | 22.25M |
| Stockholders Equity | 7.86M | 9.98M | -4.57M | -1.76M | 982.00K | -4.54M |
Cash Flow | ||||||
| Free Cash Flow | -5.71M | -6.35M | -10.02M | -8.10M | -7.57M | -24.48M |
| Operating Cash Flow | -5.69M | -6.33M | -9.38M | -7.26M | -7.43M | -22.57M |
| Investing Cash Flow | -16.02K | -12.00K | -637.00K | -836.00K | -139.00K | -1.85M |
| Financing Cash Flow | 3.59M | 3.44M | 1.09M | 6.78M | 21.43M | 4.27M |
Scinai Immunotherapeutics Technical Analysis
Negative
0.78
Price Trends
0.81
Negative
0.88
Negative
1.31
Negative
Market Momentum
-0.05
Positive
29.26
Positive
15.87
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCNI, the sentiment is Negative. The current price of 0.78 is above the 20-day moving average (MA) of 0.73, below the 50-day MA of 0.81, and below the 200-day MA of 1.31, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 29.26 is Positive, neither overbought nor oversold. The STOCH value of 15.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCNI.
Scinai Immunotherapeutics Risk Analysis
Scinai Immunotherapeutics disclosed 78 risk factors in its most recent earnings report. Scinai Immunotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Scinai Immunotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
SCNI
Scinai Immunotherapeutics
0.60
-2.20
-78.54%
GTBP
GT Biopharma
0.41
-1.99
-83.00%
ADTX
Aditxt
0.81
-4,519.19
-99.98%
CERO
CERo Therapeutics Holdings
0.03
-14.99
-99.79%
PBM
Psyence Biomedical
2.56
-28.74
-91.82%
CDT
CDT Equity
9.82
-2,660.18
-99.63%
Scinai Immunotherapeutics Corporate Events
Scinai Immunotherapeutics Shareholders Approve Share Increase, Equity Grants and Auditor at December 22 Meeting
Dec 23, 2025
On December 22, 2025, Scinai Immunotherapeutics Ltd. held its Annual Meeting of Shareholders, where investors approved a series of corporate governance and compensation measures. Shareholders re-elected director Mark Germain to serve until the thi...
Scinai Immunotherapeutics Reports Nine-Month 2025 Results and Strategic Developments
Dec 2, 2025
On December 2, 2025, Scinai Immunotherapeutics reported its financial results for the first nine months of 2025, highlighting significant growth in its CDMO business and advancements in its NanoAbs pipeline. The company saw a substantial increase ...
Scinai Immunotherapeutics Announces December 2025 Shareholder Meeting
Nov 13, 2025
Scinai Immunotherapeutics Ltd. has announced its upcoming Annual General Meeting of Shareholders, scheduled for December 22, 2025, in Tel Aviv, Israel. The meeting will address several key proposals, including the re-election of board members, ame...
Scinai Immunotherapeutics Announces Board Changes and New Accounting Firm Amid Cost-Cutting Efforts
Nov 13, 2025
Scinai Immunotherapeutics Ltd. announced the resignation of two board members, Prof. Avner Rotman and Dr. Morris Laster, effective December 31, 2025, as part of cost-cutting measures. Additionally, the company plans to replace its current accounti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.